Takeda's LIVTENCITY (maribavir) is now available through the PBS for people with post-transplant cytomegalovirus infection and disease who are resistant, refractory or intolerant to one or more prior therapies.
Takeda therapy now available through the PBS for serious viral infection
July 1, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
South Australia expands flu vax availability in response to record outbreak
July 8, 2025 - - Latest News -
MedAdvisor restates focus on US following completion of ANZ business sale
July 8, 2025 - - Latest News -
More companies are exercising their rights, and they are perfectly entitled
July 7, 2025 - - Latest News -
Neurotech’s Rett Syndrome trial results published in scientific journal
July 7, 2025 - - Australian Biotech -
PYC Therapeutics to progress polycystic kidney disease trial
July 7, 2025 - - Australian Biotech -
Pharmac minister prepares to deliver letter of expectations
July 7, 2025 - - Latest News -
UK's ten-year plan backs faster access, but industry laments lack of investment
July 7, 2025 - - Latest News